TScan Therapeutics, Inc. TCRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.11M | 9.14M | 10.33M | 8.42M | 6.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.11M | 9.14M | 10.33M | 8.42M | 6.96M |
| Cost of Revenue | 95.43M | 104.67M | 112.55M | 123.47M | 118.04M |
| Gross Profit | -88.32M | -95.53M | -102.23M | -115.04M | -111.08M |
| SG&A Expenses | 30.22M | 31.17M | 31.59M | 33.63M | 33.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.65M | 135.84M | 144.14M | 157.09M | 151.20M |
| Operating Income | -118.54M | -126.70M | -133.81M | -148.67M | -144.24M |
| Income Before Tax | -117.71M | -124.31M | -129.77M | -142.60M | -136.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -117.71 | -124.31 | -129.77 | -142.60 | -136.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.71M | -124.31M | -129.77M | -142.60M | -136.78M |
| EBIT | -118.54M | -126.70M | -133.81M | -148.67M | -144.24M |
| EBITDA | -115.66M | -123.82M | -130.95M | -145.81M | -141.12M |
| EPS Basic | -1.96 | -2.16 | -2.29 | -2.52 | -2.45 |
| Normalized Basic EPS | -1.20 | -1.33 | -1.41 | -1.56 | -1.52 |
| EPS Diluted | -1.96 | -2.16 | -2.29 | -2.52 | -2.45 |
| Normalized Diluted EPS | -1.20 | -1.33 | -1.41 | -1.56 | -1.52 |
| Average Basic Shares Outstanding | 241.53M | 230.50M | 226.99M | 226.68M | 223.28M |
| Average Diluted Shares Outstanding | 241.53M | 230.50M | 226.99M | 226.68M | 223.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |